



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

- 2 Grasselli G, Greco M, Zanella A, et al. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. *JAMA Intern Med* 2020; **180**: 1345–55.
- 3 Mikuls TR, Johnson SR, Fraenkel L, et al. American College of Rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 3. *Arthritis Rheumatol* 2021; **73**: e1–12.
- 4 Nissen CB, Sciascia S, de Andrade D, et al. The role of antirheumatics in patients with COVID-19. *Lancet Rheumatol* 2021; **3**: e447–59.
- 5 Akiyama S, Hamdeh S, Micic D, Sakuraba A. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. *Ann Rheum Dis* 2020; published online Oct 13. <https://doi.org/10.1136/annrheumdis-2020-218946>.
- 6 Glintborg B, Jensen DV, Engel S, et al. Self-protection strategies and health behaviour in patients with inflammatory rheumatic diseases during the COVID-19 pandemic: results and predictors in more than 12 000 patients with inflammatory rheumatic diseases followed in the Danish DANBIO registry. *RMD Open* 2021; **7**: e001505.
- 7 Strangfeld A, Schafer M, Gianfrancesco MA, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. *Ann Rheum Dis* 2021; published online Jan 27. <https://doi.org/10.1136/annrheumdis-2020-219498>.
- 8 Shin YH, Shin JI, Moon SY, et al. Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study. *Lancet Rheumatol* 2021; published online June 18. [https://doi.org/10.1016/S2665-9913\(21\)00151-X](https://doi.org/10.1016/S2665-9913(21)00151-X).
- 9 Bassett MT, Chen JT, Krieger N. Variation in racial/ethnic disparities in COVID-19 mortality by age in the United States: a cross-sectional study. *PLoS Med* 2020; **17**: e1003402.
- 10 Geisen UM, Berner DK, Tran F, et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. *Ann Rheum Dis* 2021; published online March 24. <https://doi.org/10.1136/annrheumdis-2021-220272>.

## Effect of the COVID-19 pandemic on patients with systemic rheumatic diseases



The effect of the COVID-19 pandemic on people with inflammatory or autoimmune rheumatic diseases remains unclear. Risk factors associated with severe COVID-19 outcomes include older age (>65 years), male sex, and pre-existing comorbidities (hypertension, diabetes, obesity, cardiovascular diseases, and chronic respiratory diseases).<sup>1</sup> Additionally, immune-compromised individuals, including people with systemic rheumatic diseases, are at increased risk of infection, including by SARS-CoV-2.<sup>2</sup>

The prevalence of COVID-19 and its association with rheumatic diseases and immunosuppressive medications have been evaluated in large population-based studies in the first phase of pandemic, from February to August, 2020. Some studies have shown a high prevalence of COVID-19 in people with inflammatory or autoimmune rheumatic diseases compared with the general population.<sup>3</sup> Furthermore, a protective role of some immunomodulatory drugs (eg, hydroxychloroquine) has been suggested by other observational studies in patients with rheumatic diseases; some of these drugs have been proposed as treatments in patients with COVID-19 who develop hyperinflammation, which is associated with severe COVID-19 outcomes.<sup>4</sup> Conflicting results, however, were initially reported in the literature about both the risk of COVID-19, and the effects of immunomodulatory drugs in patients with inflammatory or autoimmune rheumatic diseases.

More recently, increased prevalence of COVID-19 in patients with rheumatic disease has been shown by

large observational and meta-analysis studies.<sup>5</sup> Notably, differences in prevalence have been reported according to types of rheumatic disease, with patients with connective tissue diseases showing a higher prevalence of COVID-19 than patients with chronic arthritis.<sup>6</sup> Moreover, COVID-19 is more prevalent in patients with pre-existing interstitial lung disease than in those without,<sup>6</sup> and interstitial lung disease is associated with a more severe COVID-19 pneumonia, and a worse prognosis. Thus, the risks of COVID-19 in people with rheumatic diseases are complex and varied, as are the challenges faced in deciding how to reduce the risk of infection by SARS-CoV-2.

In *The Lancet Rheumatology*, Jonathan S Hausmann and colleagues<sup>7</sup> report the results of the COVID-19 Global Rheumatology Alliance Patient Experience Survey, an international online survey designed to investigate the effects of the COVID-19 pandemic on patients with rheumatic diseases worldwide. Survey questions were disseminated through websites, social media, and patient support organisations. The questionnaire included information about demographics, rheumatic disease diagnosis, COVID-19 diagnosis, protective behavioural measures adopted to reduce COVID-19 exposure, health-care access and communication with rheumatologists, medication access and changes, and changes in employment.

Responses from 9300 adult patients with rheumatic diseases were included from more than 90 countries (mean age 46.1 years [SD 12.8];

Published Online  
July 22, 2021  
[https://doi.org/10.1016/S2665-9913\(21\)00243-5](https://doi.org/10.1016/S2665-9913(21)00243-5)  
See **Articles** page e707